Literature DB >> 22082638

Antiangiogenic therapy of breast cancer: how did we get here?: the road not taken.

E Alba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22082638     DOI： 10.1007/s12094-011-0730-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  10 in total

Review 1.  Analysis of cancer signaling networks by systems biology to develop therapies.

Authors:  Rexxi D Prasasya; Dan Tian; Pamela K Kreeger
Journal:  Semin Cancer Biol       Date:  2011-04-09       Impact factor: 15.707

Review 2.  Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Authors:  Adrian M Jubb; Adrian L Harris
Journal:  Lancet Oncol       Date:  2010-12       Impact factor: 41.316

3.  VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Authors:  X Bich Trinh; P A van Dam; P B Vermeulen; S J Van Laere; G G Van den Eynden; W A A Tjalma; L Y Dirix
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 5.  Molecular mechanisms and clinical applications of angiogenesis.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

6.  Bevacizumab in metastatic breast cancer: when may it be used?

Authors:  Shari B Goldfarb; Clifford Hudis; Maura N Dickler
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

7.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

Authors:  Kristian Pietras; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

8.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

9.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

Authors:  Gabriele Bergers; Steven Song; Nicole Meyer-Morse; Emily Bergsland; Douglas Hanahan
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 10.  Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.

Authors:  Ana R Quesada; Miguel Angel Medina; Emilio Alba
Journal:  Bioessays       Date:  2007-11       Impact factor: 4.345
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.